NEW YORK (360Dx) – Sciex said today it has formed a joint venture between its diagnostics division and Chinese firm Zhejiang Dian Diagnostics around mass spec-based testing.

The venture will be based in Hangzhou, China and will develop, register, manufacture, and commercialize Class I, II and III in vitro diagnostic reagents for the SCIEX Triple Quad™ 4500MD LC-MS/MS system, Sciex said. The 4500MS received Chinese Food and Drug Administration approval earlier this year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.